State Street’s Cytosorbents Corp CTSO Stock Holding History

State Street’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.6K	Hold	7,965	–	–	﹤0.01%	4112
2026 Q1	$90.2K	Hold	7,965	–	–	﹤0.01%	4044
2025 Q4	$102K	Hold	7,965	–	–	﹤0.01%	4042
2025 Q3	$149K	Hold	7,965	–	–	﹤0.01%	3978
2025 Q2	$204K	Hold	7,965	–	–	﹤0.01%	3830
2025 Q1	$159K	Hold	7,965	–	–	﹤0.01%	3875
2024 Q4	$145K	Buy	7,965 +950	+14%	+$18.6K	﹤0.01%	3917
2024 Q3	$210K	Hold	7,015	–	–	﹤0.01%	3815
2024 Q2	$98.6K	Hold	7,015	–	–	﹤0.01%	4019
2024 Q1	$133K	Sell	7,015 -540	-7%	-$10.5K	﹤0.01%	3971
2023 Q4	$168K	Hold	7,555	–	–	﹤0.01%	3937
2023 Q3	$284K	Hold	7,555	–	–	﹤0.01%	3834
2023 Q2	$542K	Sell	7,555 -45	-0.6%	-$2.85K	﹤0.01%	3669
2023 Q1	$512K	Hold	7,600	–	–	﹤0.01%	3738
2022 Q4	$236K	Sell	7,600 -280	-4%	-$8.31K	﹤0.01%	4041
2022 Q3	$214K	Hold	7,880	–	–	﹤0.01%	4115
2022 Q2	$345K	Sell	7,880 -28,254	-78%	-$1.3M	﹤0.01%	3980
2022 Q1	$2.3M	Buy	36,134 +95	+0.3%	+$6.8K	﹤0.01%	3505
2021 Q4	$3.02M	Sell	36,039 -59	-0.2%	-$6.62K	﹤0.01%	3488
2021 Q3	$5.86M	Buy	36,098 +377	+1%	+$61.3K	﹤0.01%	3146
2021 Q2	$5.39M	Buy	35,721 +2,832	+9%	+$477K	﹤0.01%	3208
2021 Q1	$5.71M	Buy	32,889 +668	+2%	+$127K	﹤0.01%	2997
2020 Q4	$5.14M	Buy	32,221 +1,559	+5%	+$261K	﹤0.01%	2941
2020 Q3	$4.89M	Buy	30,662 +2,681	+10%	+$484K	﹤0.01%	2804
2020 Q2	$5.54M	Buy	27,981 +1,027	+4%	+$189K	﹤0.01%	2711
2020 Q1	$4.17M	Sell	26,954 -650	-2%	-$65.6K	﹤0.01%	2721
2019 Q4	$2.12M	Buy	27,604 +2,077	+8%	+$181K	﹤0.01%	3221
2019 Q3	$2.57M	Sell	25,527 -595	-2%	-$69.2K	﹤0.01%	3126
2019 Q2	$3.45M	Buy	26,122 +1,985	+8%	+$273K	﹤0.01%	3014
2019 Q1	$3.65M	Buy	24,137 +627	+3%	+$97.6K	﹤0.01%	2904
2018 Q4	$3.8M	Sell	23,510 -6	-0%	-$1.19K	﹤0.01%	2849
2018 Q3	$6.07M	Buy	23,516 +1,784	+8%	+$447K	﹤0.01%	2766
2018 Q2	$4.96M	Buy	21,732 +20,653	+1,914%	+$3.91M	﹤0.01%	2856
2018 Q1	$153K	Buy	1,079 +144	+15%	+$21.8K	﹤0.01%	3582
2017 Q4	$122K	Buy	935 +335	+56%	+$42.6K	﹤0.01%	3594
2017 Q3	$74K	Hold	600	–	–	﹤0.01%	3649
2017 Q2	$51K	Hold	600	–	–	﹤0.01%	3592
2017 Q1	$54K	Hold	600	–	–	﹤0.01%	3571
2016 Q4	$65K	Hold	600	–	–	﹤0.01%	3546
2016 Q3	$77K	Hold	600	–	–	﹤0.01%	3462
2016 Q2	$55K	Hold	600	–	–	﹤0.01%	3583
2016 Q1	$47K	Hold	600	–	–	﹤0.01%	3620
2015 Q4	$67K	Hold	600	–	–	﹤0.01%	3576
2015 Q3	$75K	Hold	600	–	–	﹤0.01%	3556
2015 Q2	$73K	Hold	600	–	–	﹤0.01%	3560
2015 Q1	$158K	Buy	+600	New	+$123K	﹤0.01%	3510

Other funds holding CTSO

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street's CTSO Position: Q2 2026 in Review

State Street held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 7,965 shares worth $59.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4112.

State Street first reported a position in CTSO in Q1 2015 and has held it in 46 quarters since. The position peaked at $6.07M in Q3 2018. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

State Street held 7,965 shares of Cytosorbents Corp worth $59.6K as of Q2 2026.
State Street left its Cytosorbents Corp share count unchanged in Q2 2026.
Cytosorbents Corp made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4112 holding.
State Street first reported a position in Cytosorbents Corp in Q1 2015 and has held it in 46 quarters since.
State Street's Cytosorbents Corp position peaked at $6.07M in Q3 2018.
47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.